相关实验视频

Updated: Jan 11, 2026

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

TP53突变预测了在肝脏内胆固醇癌中对基于免疫检查点抑制剂的治疗的耐药性

Hiroki Inada^1,2, Sotaro Kurano¹, Hideaki Miyamoto^1,2

¹Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Graduate School of Medical Sciences, Kumamoto University, 1-1-1, Honjo, Chuo-Ku, Kumamoto, 860-8556, Japan.

Journal of gastroenterology

|November 17, 2025

概括

TP53突变预测肝脏内胆管癌 (ICC) 免疫检查点抑制剂治疗的反应不佳. 这一发现揭示了TP53-突变ICC中的免疫逃避表型,指导了未来的免疫治疗策略.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
基因组学就是基因组学.

背景情况:

肝脏内胆管癌 (ICC) 是一种具有有限治疗选择的侵袭性癌症.
免疫检查点抑制剂 (ICI) 治疗在ICC患者中显示出不同的反应.
缺乏可靠的生物标志物来预测ICC治疗疗效.

研究的目的:

在ICC中识别能够预测ICI化疗反应的分子生物标志物.
调查与治疗反应或耐药性相关的免疫微环境.

主要方法:

对25名无法切除的ICC患者进行了回顾性分析,这些患者接受了凝丁,思丁和杜尔瓦卢马布 (GCD) 治疗.
对19名患者进行全面的基因组分析,以确定基因组的改变.
使用Xenium平台进行空间转录组分析,以表征瘤与免疫相互作用.

主要成果:

无进展生存时间 (PFS) 中位数为7.8个月;总生存时间 (OS) 中位数为11.1个月.
TP53突变是短PFS的唯一独立预测因子 (HR:4.20,p=0.036).
突变TP53的瘤表现出一种免疫抑制的微环境,减少了CD8+T细胞透和抗原呈现.

结论:

在ICC中,TP53突变被确定为ICI治疗耐药性的预测生物标志物.
空间分析显示TP53-突变ICC.中的免疫逃避型表型.
这些发现支持针对ICC开发TP53指导的免疫治疗策略.

关键词:

这种突变是TP53突变.综合性基因组分析分析免疫检查点抑制剂免疫检查点抑制剂在肝脏内发生的胆管癌,胆管癌.空间转录组学空间转录组学

更多相关视频

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

相关概念视频

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.